Novartis Factor B inhibitor grabs priority review in IgAN

Phase 3Clinical ResultDrug ApprovalPriority Review
Already armed with an approval in paroxysmal nocturnal hemoglobinuria, Novartis' Factor B inhibitor, Fabhalta, has nabbed a priority review tag in IgA nephropathy (IgAN).
According to Novartis, the APPLAUSE-IgAN trial of Fabhalta is the first and only phase 3 study to demonstrate significant proteinuria (protein in urine) reduction by targeting the complement system in patients with IgAN, a rare kidney disease that can progress to kidney failure within 10 years.
Results from a pre-specified interim analysis demonstrated that patients treated with Fabhalta achieved a 38.3% proteinuria reduction at 9 months when compared to placebo on top of supportive care.
If approved in IgAN, Fabhalta would be the first treatment that specifically targets the alternative complement pathway.
Fabhalta was first approved by the FDA back in December, becoming the first oral monotherapy for the treatment of adults with a rare, chronic blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH).
The standard of care for PNH, C5 inhibitorC5 inhibitor treatments administered as infusions, may leave symptoms, including hemolysis, bone marrow failure and thrombosis, uncontrolled. While over one-third of patients on anti-C5 treatments require blood transfusions at least once per year, in Novartis' phase 3 APPLY-PNH trial, nearly all patients treated with Fabhalta did not receive blood transfusions.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.